Page last updated: 2024-12-11

pranidipine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pranidipine: structure given in UD 37:228m [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6436048
SCHEMBL ID49274
MeSH IDM0138725

Synonyms (34)

Synonym
acalas
opc-13340
pranidipine
methyl cinnamyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 3-phenyl-2-propenyl ester, (e)-
trans-cinnamyl methyl 4-(3-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
frc-8411
pranidipine [inn]
ccris 6666
frc 8411
brn 5654325
(e)-cinnamyl methyl (+-)-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
opc 13340
3-cinnamyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3-o-methyl 5-o-[(e)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
99522-79-9
unii-9des9qvh58
9des9qvh58 ,
S2436
pranidipine [jan]
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl (2e)-3-phenyl-2-propenyl ester
(e)-cinnamyl methyl (+/-)-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-methyl 5-((2e)-3-phenyl-2-propen-1-yl) ester
AKOS025311508
SCHEMBL49274
smr004701255
MLS006010122
HY-19664
CS-0016176
DTXSID00875518
(z)-3-methyl 5-(3-phenylallyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
AS-15993
Q7238365
AKOS040742443

Research Excerpts

Overview

Pranidipine is an optically-active 1,4-dihydropyridine (DHP) voltage-dependent L-type calcium channel inhibitor. It is being developed for clinical use as an antihypertensive and antianginal drug.

ExcerptReferenceRelevance
"Pranidipine (OPC-13340) is a novel, potent and long-acting 1,4-dihydropyridine derivative Ca-antagonist being developed for clinical use as an antihypertensive and antianginal drug. "( [Effects of pranidipine (OPC-13340), a novel 1,4-dihydropyridine derivative Ca-antagonist, on isolated porcine coronary contraction and acute myocardial ischemia in the pig].
Ikezono, K; Mori, T; Nakayama, N; Ohura, M; Tominaga, M; Watanabe, K; Yabuuchi, Y, 1994
)
2.11
"Pranidipine is an optically-active 1,4-dihydropyridine (DHP) voltage-dependent L-type calcium channel inhibitor. "( Differential properties of the optical-isomers of pranidipine, a 1,4-dihydropyridine calcium channel modulator.
Fujiki, H; Hirano, T; Ikezono, K; Kido, M; Mori, T; Nakayama, N; Ohura, M; Orito, K; Sumida, T; Toide, K; Yabuuchi, Y; Yoshida, K, 1999
)
2

Actions

ExcerptReferenceRelevance
"Pranidipine prevented an increase in the weight of the left and right ventricles (2.02 +/- 0.04 and 0.6 +/- 0.03g/kg, P < 0.01) and LVDd (7.9 +/-0.2mm, P < 0.01 to MI)."( Long-acting calcium channel antagonist pranidipine prevents ventricular remodeling after myocardial infarction in rats.
Omura, T; Otsuka, R; Shimada, Y; Takeuchi, K; Ujino, K; Yoshida, K; Yoshikawa, J; Yoshiyama, M, 1999
)
1.29

Treatment

ExcerptReferenceRelevance
"Pranidipine treatment did not inhibit collar-induced intimal thickening."( The effects of calcium channel blockers are not related to their chemical structure in the collar model of the rabbit.
Ertuna, E; Kerry, Z; Ozer, A; Reel, B; Yasa, M; Yetik Anacak, G,
)
0.85

Bioavailability

ExcerptReferenceRelevance
"Oral co-administration with grapefruit juice and pranidipine was associated with increased bioavailability and changed the pharmacodynamics of pranidipine, particularly with regard to heart rate."( Interaction of citrus juices with pranidipine, a new 1,4-dihydropyridine calcium antagonist, in healthy subjects.
Azuma, J; Hashimoto, K; Kudo, S; Matsuoka, O; Okamoto, T; Onnagawa, O; Sekino, H; Shirafuji, T,
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Voltage-dependent L-type calcium channel subunit alpha-1COryctolagus cuniculus (rabbit)IC50 (µMol)0.03700.03700.06430.1070AID478862
Voltage-dependent L-type calcium channel subunit alpha-1DRattus norvegicus (Norway rat)IC50 (µMol)0.03700.00131.991510.0000AID478861
Histamine H2 receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.03700.00402.15557.2000AID478861
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID478862Antagonist activity at rabbit Cav1.2 expressed in HEK293 cells assessed as inhibition of voltage pulse-induced calcium current by FLIPR calcium 4 assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
AID478863Selectivity ratio of IC50 for rabbit Cav1.2 to IC50 for rat Cav1.32010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
AID478861Antagonist activity at rat Cav1.3 expressed in HEK293 cells assessed as inhibition of voltage pulse-induced calcium current by FLIPR calcium 4 assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.06)18.7374
1990's21 (63.64)18.2507
2000's9 (27.27)29.6817
2010's1 (3.03)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.44 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index5.49 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (8.33%)5.53%
Reviews2 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (86.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]